Monday, 22 Jan 2018

You are here

Frequency of Rheumatoid Knee Replacements Down in the Biologic Era

A time-series analysis of incident rheumatoid arthritis (RA) patients seen between 1996 and 2011 in the Danish National Patient Register shows that the incidence of hip (THR) and knee replacements (TKR) began to decrease after the introdution of biologic agents for RA in 2002.

RA patents were matched (age, sex, geography) 1:10 with general population comparators (GPCs). Standardized 5-year incidence rates of THR and TKR surgery were reported from 1996–2001 and compared with the bDMARD era (2003–2016) after the 2002 Danish guidelines introduced biologics for use in RA.

They compared THR and TKR rates between 30 404 RA patients and 297916 GPCs.

Among patients with RA, the incidence rate of TKR increased from 1996 to 2001, but started to decrease from 2003 and throughout the bDMARD era. The incidence of TKR increased among GPCs from 1996 to 2016.

Knee replacement Rates in RA 1996-2012

In 1996, the incidence rate of THR and TKR was 3-fold and 14-fold higher, respectively among patients with RA compared with GPCs in 1996. The introduction of biologics resulted in decreasing TKR rates.

The incidence of THR had started to decrease before bDMARD introduction in 2003.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Weight Loss Linked to RA Improvement

By retrospectively reviewing electronic health record (EHR) data, Kreps et al found that rheumatoid arthritis (RA) patients who lost >5 kg of weight were three times more likely to demonstrate improvement in disease activity.

Researchers investigated the association between weight loss and CDAI change among patients who were overweight/obese at baseline and who lost weight during follow-up.

IL-1 and IL-6 Inhibition Preferred in Systemic JIA

Since 2000, the German Biologics register (BiKeR) has prospectively enrolled children with juvenile idiopathic arthritis to assess outcomes with biologic therapies.  A new report evaluates the efficacy and safety of etanercept (ETA), tocilizumab (TOC) and the interleukin-1 inhibitors (anakinra and canakinumab) (IL-1i) in those with systemic onset juvenile idiopathic arthritis JIA (sJIA).

Increasing Adverse Events Seen with Higher Disease Activity in Early RA

Researchers in the NEO-RACo Study Group studied adverse events (AEs) in relation to disease activity in patients with early rheumatoid arthritis (RA).

Small Joint Surgeries Drop Among RA Patients

The rate of small - but not large - joint surgery has dropped among patients with rheumatoid arthritis since 1995, a retrospective review of orthopedic surgeries found. By 2015, less than 1% of patients per year underwent small joint surgery, reported Ashima Makol, MD, of the Mayo Clinic in Rochester, Minnesota, and colleagues in Arthritis Care & Research. 

Despite Increasing Metric Use, They Are Not Widespread in Rheumatoid Care

The Journal of Rheumatology has published a nationwide survey of US rheumatologists and shown that despite trends for increasing metric assessments, nearly half of rheumatoid arthritis (RA) patients are not routinely assessed with a disease activity metric and the evidence they use these in a treat-to-target (T2T) practice is lacking.